Epstein Secrets

liding scale, can result In an attractively skewed upside vs downside profile for holding the mandatory convert vs the common stock. EFTA00821588 Allergan, Teva and Frontier Communications are three names we have high conviction on and they have mandatory convert preferreds that I recommend buying. All

TEVA's positioning In generic pharma where scale and product diversity are increasingly important. TWA remains one of our top picks In Spec Pharma. Frontier Comm (FTR) - BAML reaffirming BUY after Frontier reported its first post-Verizon assets merger results. FTR's earnings miss was due to a decline in the le

version ratio sliding scale, can result in an att=actively skewed upside vs downside profile for holding the mandatory conve=t vs the common stock. Allergan, Teva and Frontier Communications are three names we have hi=h conviction on and they have mandatory convert preferreds that I recommend buying. Al

EVA's positioning in generic pharma where scale and pro=uct diversity are increasingly important. TEVA remains one of our top pick= in Spec Pharma. Frontier Comm (FTR) - BAM= reaffirming BUY after Frontier reported its first post-Verizon assets merger results. =TR's earnings miss was due to a decline in the l

version ratio sliding scale, can result in an attractively skewed upside vs downsi=e profile for holding the mandatory convert vs the common stock. Allergan, Teva and Frontier Communications ar= three names we have high conviction on and they have mandatory convert pr=ferreds that I recommend buying. 3

ositioning in generic=pharma where scale and product diversity are increasingly important. TEVA =emains one of our top picks in Spec Pharma.<=span> Frontier Comm (FTR) - BAML reaffirming BUY after Frontier reported its first post-Verizon assets merger results. FTR's earnings miss was due to a=decline in the l

version ratio sliding scale, can result in an att=actively skewed upside vs downside profile for holding the mandatory conve=t vs the common stock. Allergan, Teva and Frontier Communications are three names we have hi=h conviction on and they have mandatory convert preferreds that I recommend buying. 7

EVA's positioning in generic pharma where scale and pro=uct diversity are increasingly important. TEVA remains one of our top pick= in Spec Pharma. Frontier Comm (FTR) - BAM= reaffirming BUY after Frontier reported its first post-Verizon assets merger results. =TR's earnings miss was due to a decline in the l

ersion ratio sliding scale, can result in an attractively skewed upside vs downside profile for holding the mandatory convert vs the common stock. Allergan, Teva and Frontier Communications are three names we have high conviction on and they have mandatory convert preferreds that I recommend buying. EF

EVA's positioning in generic pharma where scale and product diversity are increasingly important. TEVA remains one of our top picks in Spec Pharma. Frontier Comm (FIR) - BAML reaffirming BUY after Frontier reported its first post-Verizon assets merger results. FTR's earnings miss was due to a decline in the l

version ratio sliding scale, can result in an attractively skewed upside vs downside profile for holding the mandatory convert vs the common stock. Allergan, Teva and Frontier Communications are three names we have high conviction on and they have mandatory convert preferreds that I recommend buying. Al

EVA's positioning in generic pharma where scale and product diversity are increasingly important. TEVA remains one of our top picks in Spec Pharma. Frontier Comm (FTR) - BAML reaffirming BUY after Frontier reported its first post-Verizon assets merger results. FTR's earnings miss was due to a decline in the l

version ratio sliding scale, can result in an attractively skewed upside vs downside profile for holding the mandatory convert vs the common stock. Allergan, Teva and Frontier Communications are three names we have high conviction on and they have mandatory convert preferreds that I recommend buying. Al

EVA's positioning in generic pharma where scale and product diversity are increasingly important. TEVA remains one of our top picks in Spec Pharma. Frontier Comm (FTR) - BAML reaffirming BUY after Frontier reported its first post-Verizon assets merger results. FTR's earnings miss was due to a decline in the l

version ratio sliding scale, can result in an att=actively skewed upside vs downside profile for holding the mandatory conve=t vs the common stock. Allergan, Teva and Frontier Communications are three names we have hi=h conviction on and they have mandatory convert preferreds that I recommend buying. Al

EVA's positioning in generic pharma where scale and pro=uct diversity are increasingly important. TEVA remains one of our top pick= in Spec Pharma. Frontier Comm (FTR) - BAM= reaffirming BUY after Frontier reported its first post-Verizon assets merger results. =TR's earnings miss was due to a decline in the l

version ratio sliding scale, can result in an attractively skewed upside vs downside profile for holding the mandatory convert vs the common stock. Allergan, Teva and Frontier Communications are three names we have high conviction on and they have mandatory convert preferreds that I recommend buying. Al

EVA's positioning in generic pharma where scale and product diversity are increasingly important. TEVA remains one of our top picks in Spec Pharma. Frontier Comm (FTR) - BAML reaffirming BUY after Frontier reported its first post-Verizon assets merger results. FTR's earnings miss was due to a decline in the l